The successful clinical application of antibody-based therapeutics initially triggered the generation of various high-throughput and reliable antibody discovery platforms, each with its own unique advantages.

Today, as the immuno-oncology field strives to develop the next wave of safe, efficacious antibody therapeutics, the question has become: how can we best leverage these tools and approaches to maximize the potential for success in both translational and clinical R&D?

During this webinar, ImmunoPrecise Antibodies (IPA) will present a case study exploring the high-throughput identification of genetically distinct, target-specific antibodies as the driving force behind a streamlined, end-to-end antibody discovery and development pipeline. A multi-stakeholder panel including industry experts and a leading immuno-oncology clinician will then discuss key considerations for novel antibody therapeutic research from the clinical development perspective.

Attendees will discover:

• How to run a solid and strong antibody discovery campaign in a relatively short timeframe.
• The direct correlation between the success of a complex antibody discovery campaign, the robustness of the antibody discovery technologies used, and optimized developability analysis.
• How to overcome tolerance issues, allowing for more reliable preclinical evaluation of lead candidates without reliance on surrogate antibodies.
• Keys to preparing for translational and clinical success with novel antibody-based therapeutic technologies.